BNP Paribas Financial Markets
BBOT

BNP Paribas Financial Markets’s BridgeBio Oncology BBOT Stock Holding History

BNP Paribas Financial Markets’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$813K Buy
90,819
+64,347
+243% +$691K ﹤0.01% 3279
2025
Q4 		$331K Buy
+26,472
New +$321K ﹤0.01% 3805

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Financial Markets's BBOT Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its BridgeBio Oncology (BBOT) stake by 243% in Q1 2026, buying an estimated $691K and bringing the position to 90,819 shares worth $813K. The position accounts for ﹤0.01% of the portfolio, ranked #3279.

BNP Paribas Financial Markets first reported a position in BBOT in Q4 2025 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • BNP Paribas Financial Markets held 90,819 shares of BridgeBio Oncology worth $813K as of Q1 2026.
  • BNP Paribas Financial Markets bought 64,347 BridgeBio Oncology shares in Q1 2026, an estimated $691K.
  • BridgeBio Oncology made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3279 holding.
  • BNP Paribas Financial Markets first reported a position in BridgeBio Oncology in Q4 2025 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.